Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradsh...
Κύριοι συγγραφείς: | Mahida, Y, Jewell, D |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
1990
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.
ανά: Selby, W, κ.ά.
Έκδοση: (1984) -
Macrophage and lymphocyte subpopulations in magnifying endoscopic lesions of Crohn's disease.
ανά: Gionchetti, P, κ.ά.
Έκδοση: (1988) -
DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET
ανά: Alvaro Mitsunori NISHIKAWA, κ.ά. -
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.
ανά: Mahida, Y, κ.ά.
Έκδοση: (1989) -
Comparative Trial of Remission Prophylaxis in Quiescent Crohn’s Disease with Oral 4-Aminosalicyclic Acid Versus 5-Aminosalicylic Acid Slow Release Tablets
ανά: Stefanie Howaldt, κ.ά.
Έκδοση: (1993-01-01)